Tissue | Expression Dynamics | Abbreviation |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001049826 | Esophagus | HGIN | proteasomal protein catabolic process | 139/2587 | 490/18723 | 1.20e-17 | 3.41e-15 | 139 |
GO:004316126 | Esophagus | HGIN | proteasome-mediated ubiquitin-dependent protein catabolic process | 114/2587 | 412/18723 | 7.00e-14 | 1.20e-11 | 114 |
GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
GO:0043161111 | Esophagus | ESCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 312/8552 | 412/18723 | 3.53e-36 | 4.48e-33 | 312 |
GO:00454449 | Esophagus | ESCC | fat cell differentiation | 135/8552 | 229/18723 | 3.38e-05 | 2.78e-04 | 135 |
GO:00319294 | Esophagus | ESCC | TOR signaling | 79/8552 | 126/18723 | 8.57e-05 | 6.21e-04 | 79 |
GO:00320061 | Esophagus | ESCC | regulation of TOR signaling | 63/8552 | 104/18723 | 1.55e-03 | 7.29e-03 | 63 |
GO:00311461 | Esophagus | ESCC | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process | 33/8552 | 49/18723 | 1.80e-03 | 8.26e-03 | 33 |
GO:001049812 | Liver | Cirrhotic | proteasomal protein catabolic process | 216/4634 | 490/18723 | 2.52e-21 | 9.29e-19 | 216 |
GO:004316112 | Liver | Cirrhotic | proteasome-mediated ubiquitin-dependent protein catabolic process | 184/4634 | 412/18723 | 4.52e-19 | 8.85e-17 | 184 |
GO:00319292 | Liver | Cirrhotic | TOR signaling | 44/4634 | 126/18723 | 6.69e-03 | 3.30e-02 | 44 |
GO:00454442 | Liver | Cirrhotic | fat cell differentiation | 73/4634 | 229/18723 | 8.57e-03 | 3.97e-02 | 73 |
GO:001049822 | Liver | HCC | proteasomal protein catabolic process | 351/7958 | 490/18723 | 6.92e-40 | 1.46e-36 | 351 |
GO:004316122 | Liver | HCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 299/7958 | 412/18723 | 7.82e-36 | 8.27e-33 | 299 |
GO:00319291 | Liver | HCC | TOR signaling | 78/7958 | 126/18723 | 8.49e-06 | 9.97e-05 | 78 |
GO:0032006 | Liver | HCC | regulation of TOR signaling | 63/7958 | 104/18723 | 1.50e-04 | 1.20e-03 | 63 |
GO:00454441 | Liver | HCC | fat cell differentiation | 120/7958 | 229/18723 | 1.52e-03 | 8.05e-03 | 120 |
GO:0031146 | Liver | HCC | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process | 30/7958 | 49/18723 | 6.31e-03 | 2.57e-02 | 30 |
GO:001049820 | Oral cavity | OSCC | proteasomal protein catabolic process | 336/7305 | 490/18723 | 5.45e-41 | 8.63e-38 | 336 |
GO:004316120 | Oral cavity | OSCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 285/7305 | 412/18723 | 5.68e-36 | 5.99e-33 | 285 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FBXO9 | SNV | Missense_Mutation | novel | c.301N>A | p.Ala101Thr | p.A101T | Q9UK97 | protein_coding | deleterious(0.01) | probably_damaging(0.987) | TCGA-FI-A2F4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FBXO9 | insertion | In_Frame_Ins | novel | c.769_770insGAATTTTCCACTCACTCAGTGTACTACAGTTGTACC | p.Met257delinsArgIlePheHisSerLeuSerValLeuGlnLeuTyrLeu | p.M257delinsRIFHSLSVLQLYL | Q9UK97 | protein_coding | | | TCGA-B5-A11Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FBXO9 | deletion | Frame_Shift_Del | novel | c.20delN | p.Phe8SerfsTer51 | p.F8Sfs*51 | Q9UK97 | protein_coding | | | TCGA-SJ-A6ZI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FBXO9 | SNV | Missense_Mutation | novel | c.13A>G | p.Ile5Val | p.I5V | Q9UK97 | protein_coding | deleterious_low_confidence(0) | benign(0) | TCGA-3K-AAZ8-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Targeted Molecular therapy | sorafenib | PD |
FBXO9 | SNV | Missense_Mutation | | c.566C>T | p.Ser189Leu | p.S189L | Q9UK97 | protein_coding | deleterious(0) | possibly_damaging(0.791) | TCGA-66-2759-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Chemotherapy | carboplatin | CR |
FBXO9 | SNV | Missense_Mutation | novel | c.1319C>T | p.Thr440Ile | p.T440I | Q9UK97 | protein_coding | deleterious(0) | benign(0.066) | TCGA-LA-A446-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
FBXO9 | SNV | Missense_Mutation | novel | c.415N>T | p.Gly139Cys | p.G139C | Q9UK97 | protein_coding | tolerated(0.05) | benign(0.011) | TCGA-O2-A5IB-01 | Lung | lung squamous cell carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
FBXO9 | SNV | Missense_Mutation | novel | c.755N>T | p.Thr252Met | p.T252M | Q9UK97 | protein_coding | tolerated(0.1) | benign(0.058) | TCGA-HD-8634-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FBXO9 | SNV | Missense_Mutation | novel | c.1201A>G | p.Ile401Val | p.I401V | Q9UK97 | protein_coding | tolerated(1) | benign(0) | TCGA-KU-A66S-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
FBXO9 | SNV | Missense_Mutation | rs765535059 | c.1118G>A | p.Arg373His | p.R373H | Q9UK97 | protein_coding | deleterious(0.01) | benign(0.036) | TCGA-BR-8680-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR |